Literature DB >> 31385215

The Stage IV Shuffle: Elusiveness of Straight Talk About Advanced Cancer.

Donald A Brand1.   

Abstract

During the initial consultation with a patient to communicate a diagnosis of late-stage cancer, the oncologist may refrain from giving survival statistics, redirecting the conversation from the bad news (incurability) to the practical aspects of the patient's care (treatments, timetables, appointments, and testing to monitor response to treatment). Whether conscious or unconscious, this diversion helps cushion the impact of the disturbing news. This paper shows that clinicians' gingerly handling of harsh facts when they talk with patients also applies to health educators and researchers when they write about late-stage cancer. As a result, these cancer patients typically lack an understanding of their poor prognosis and the limited effectiveness of most available treatments, possibly compromising their ability to make informed choices. To remedy this problem, I describe an approach to straight talk about late-stage cancer that can give a patient realistic hopes instead of false hopes that are apt to betray later on. I also propose an enhanced method of displaying and interpreting comparative efficacy data that can facilitate understanding and serve as a basis for shared decision making.

Entities:  

Keywords:  cancer; communication; ethics; patient engagement

Year:  2019        PMID: 31385215      PMCID: PMC6848670          DOI: 10.1007/s11606-019-05158-5

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  19 in total

1.  Breast cancer treated with fluorouracil. Survival studies in advanced stages.

Authors:  R J Samp; F J Ansfield
Journal:  JAMA       Date:  1966-11-14       Impact factor: 56.272

2.  Prognosis, Treatment Benefit and Goals of Care: What do Oncologists Discuss with Patients who have Incurable Cancer?

Authors:  W Raskin; I Harle; W M Hopman; C M Booth
Journal:  Clin Oncol (R Coll Radiol)       Date:  2015-12-14       Impact factor: 4.126

3.  Patients' expectations about effects of chemotherapy for advanced cancer.

Authors:  Jane C Weeks; Paul J Catalano; Angel Cronin; Matthew D Finkelman; Jennifer W Mack; Nancy L Keating; Deborah Schrag
Journal:  N Engl J Med       Date:  2012-10-25       Impact factor: 91.245

4.  CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials.

Authors:  Kenneth F Schulz; Douglas G Altman; David Moher
Journal:  BMJ       Date:  2010-03-23

Review 5.  Patient centered decision making in palliative cancer treatment: a world of paradoxes.

Authors:  Hanneke de Haes; Nelleke Koedoot
Journal:  Patient Educ Couns       Date:  2003-05

Review 6.  Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival.

Authors:  Julia Wilkerson; Tito Fojo
Journal:  Cancer J       Date:  2009 Sep-Oct       Impact factor: 3.360

Review 7.  Chemotherapeutic management of stage IV non-small cell lung cancer.

Authors:  Mark A Socinski; David E Morris; Gregory A Masters; Rogerio Lilenbaum
Journal:  Chest       Date:  2003-01       Impact factor: 9.410

8.  Patients' Preferences for Information About the Benefits and Risks of Second-Line Palliative Chemotherapy and Their Oncologist's Awareness of These Preferences.

Authors:  Linda J M Oostendorp; Petronella B Ottevanger; Agnes J van de Wouw; Aafke H Honkoop; Maartje Los; Winette T A van der Graaf; Peep F M Stalmeier
Journal:  J Cancer Educ       Date:  2016-09       Impact factor: 2.037

9.  What oncologists tell patients about survival benefits of palliative chemotherapy and implications for informed consent: qualitative study.

Authors:  Suzanne Audrey; Julian Abel; Jane M Blazeby; Stephen Falk; Rona Campbell
Journal:  BMJ       Date:  2008-07-31

10.  Characteristics, survival, and related factors of newly diagnosed colorectal cancer patients refusing cancer treatments under a universal health insurance program.

Authors:  Chun-Yi Liu; William Tzu-Liang Chen; Pei-Tseng Kung; Chang-Fang Chiu; Yueh-Hsin Wang; Shwn-Huey Shieh; Wen-Chen Tsai
Journal:  BMC Cancer       Date:  2014-06-17       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.